Abstract:Objective: To compare the differences in the clinicopathological and molecular biological features between the breast cancer patients with estrogen receptor (ER) + /progesterone receptor (PR) + or ER + /PR - tumors. Methods: The clinicopathological data of 3124 female breast cancer patients with known ER/PR expression status, 2220 being ER + /PR + and 904 being ER + /PR -, and 1484 being ER - /PR -, were analyzed retrospectively. Immunohistochemistry was used to detect the expression of c-erb and cathapsin D in the tumor specimens. Results: The average peak onset age was 50 years in both the ER + /PR + and ER + PR- patients, and the mean age of the ER + /PR + patients was 52.40 years, not significantly different from that of the ER - /PR - patients (52.57 years, P = 0.709). The peak onset age of the ER + patients was 50 years, significantly higher that that of the ER - patients (48 years, P = 0.001), and the mean age of the ER + patients was 52.46 years, significantly higher than that of the ER - patients (51.42 years, P = 0.001). Univariate analysis showed that ER + /PR - tumors tended to be larger. 24.8% of the ER + /PR- patients had 4 or more metastatic lymph nodes, a rate significantly higher than that of the ER + /PR - patients (20.7%, P = 0.004). The tumors of 18% of the ER + /PR - patients were at the grade III, a rate significantly higher than that of the ER + /PR + patients (13.5%, P = 0.008). The strong positivity rate of the ER + /PR + tumors was 23.4%, ignorantly higher than hat of the ER + /PR - tumors (11.2%, P = 0.000). The c-erB-2 positive rate of the ER + /PR + tumors was 19.7%, significantly lower than that of the ER + /PR - tumor group (28.7%, P = 0.000). The cathepsin D positive rate of the ER + /PR - group was 76.9%, significantly higher than that of the ER + /PR- group (71.9%, P = 0.005). Multivariate analysis indicated that positive PR expression was associated with the level of ER (OR = 1.792,95% CI = 1.484-2.164, P = 0.000), cathepsin D(OR = 1.380,95% CI = 1.023 - 1.862,P = 0.035) and c-erbB-2(OR = 0.639,95% CI = 0.463 - 0.883,P = 0.007). Conclusion: ER + /PR + and ER + /PR - tumors may have identical etiology. The mechanism of whether PR is expressed in ER + breast cancer may be caused by different factors, which causing many different aspects. According to these differences, new target of therapy may provide the possibility of improving the response and prognosis for patients with ER + /PR - tumors.

Differences in the Expression of 4 Progesterone Receptor Antibodies EP2, SP2, 1e2,and 16 in Non-Specific Invasive Breast Cancers

Expressions of Progesterone Receptor a and B in Breast Invasive Ductal Carcinoma and Their Clinical Significance

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

[Reliability of Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer Evaluated by Immunohistochemistry].

Clinico-pathological features of ER+/PR+ and ER+/PR-breast tumors:a comparative study of 5211 cases

Expression of C-erbB-2 Protein in Different Sliding Techniques of Breast Cancer

Retrospective study of the differences of biomarker expression between primary lesions of breast cancer and corresponding lymph node metastases

Progesterone receptor and its correlation with DNA-binding function of estrogen receptor in human breast cancer

Expression of Androgen Receptor and Embryonic Stem Cell Associated Transcript 4 in Breast Cancer Patients with Over-Expression of Human Epidermal Growth Factor Receptor 2 and Their Clinical Significances

Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy

[Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].

Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.

Clinical Significance of Progesterone Receptors A and B Expressions in Endometrial Carcinomas

A Comparison Of Tumor Characteristics Between Er Plus /Pr Plus And Er Plus /Pr- Breast Tumors In Chinese Women

Progesterone Receptor and Progesterone Receptor B Isoform Expression and Their Clinical Significance in Endometrial Adenocarcinoma

Expression of ER,PR, C-erbB-2 and Ki-67 Genes in Breast Cancer and Their Clinical Significance

[Concordance of PD-L1 Expression Detected by Two Immunohistochemical Platforms and Antibodies].

Clinical and X-ray characteristics for expressions of different receptors in patients with breast cancer

Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study

The Potential Biomarkers in Predicting Pathologic Response of Breast Cancer to Three Different Chemotherapy Regimens: a Case Control Study

Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression Rates in Invasive Breast Carcinoma: A Study of 21 Institutions